Previous 10 | Next 10 |
Second Quarter 2019 Results : Record billable tests of 16,369, growing 187% year over year Record revenue of $8.4 million, growing 56% year over year Gross Margin improves more than 12 percentage points sequentially; cost per test improves by 44% sequentially Posts profit; GAAP inco...
TEMPLE CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of Linda Marsh, Senior Executive Vice President of AHMC Healthcare, Inc. to it...
TEMPLE CITY, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (NGS) solutions, today announced that the company has received...
Genetic testing services providers are in the green after UnitedHealthcare instituted coverage for Myriad Genetics' GeneSight test for major depressive disorder. More news on: NeoGenomics, Inc., Invitae Corporation, Biocept, Inc., Healthcare stocks news, Stocks on the move, Read...
TEMPLE CITY, Calif., July 22, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its second quarter 2019 financial results after the market closes on Monday August 5, 2019. The...
TEMPLE CITY, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) and the Parkinson’s Foundation today announced a collaboration on a new genetic testing initiative for individuals living with Parkinson’s Disease (PD). The nation-wide initiative, called PD...
Fulgent Genetics, Inc. (FLGT) Q1 2019 Results Earnings Conference Call May 07, 2019, 04:30 PM ET Company Participants Nicole Borsje - Head of Investor Relations Ming Hsieh - Chief Executive Officer Paul Kim - Chief Financial Officer Conference Call Participants Presentatio...
Fulgent Genetics (NASDAQ: FLGT ): Q1 Non-GAAP EPS of -$0.06 misses by $0.05 ; GAAP EPS of -$0.10 misses by $0.03 . More news on: Fulgent Genetics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
First Quarter 2019 Results : Revenue totals $5.4 million, growing 15% year over year Billable tests delivered total 7,530, growing 63% year over year GAAP loss of $1.9 million, or $0.10 per share Non-GAAP loss of $1.0 million, or $0.06 per share Adjusted EBITDA loss of $712,000 Ca...
Aurora Cannabis (NYSE: ACB ) initiated with Buy rating and C$16.50 (35% upside) price target at Desjardins. Shares up 1% premarket on the heels of its license deal with EnWave. More news on: Aurora Cannabis Inc., Gilead Sciences, Inc., Tocagen Inc., Healthcare stocks news, Stoc...
News, Short Squeeze, Breakout and More Instantly...
Fulgent Genetics Inc. Company Name:
FLGT Stock Symbol:
NASDAQ Market:
Fulgent Genetics Inc. Website:
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2024 financial results bef...
2024-03-22 14:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-01 23:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...